Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Disease in Children: Long-Term Outcomes of Medical Therapy
source: Clinical Endocrinology
year: 2016
authors: Rabon S, Burton AM, White PC
summary/abstract:Background and Objectives:
Management options are limited for the treatment of Graves’ disease, and there is controversy regarding optimal treatment. We describe the demographic and biochemical characteristics of children with Graves’ disease and the outcomes of its management.
Methods:
This is a retrospective study reviewing medical records from 2001 to 2011 at a tertiary-care paediatric hospital. Diagnostic criteria included elevated free T4 and total T3, suppressed TSH, and either positive thyroid-stimulating immunoglobulin or thyroid receptor antibodies or clinical signs suggestive of Graves’ disease, for example exophthalmos. Patients were treated with antithyroid drugs (ATD), radioactive iodine, or thyroidectomy. The main outcome measures were remission after medical therapy for at least 6 months and subsequent relapse.
Results:
A total of 291 children met diagnostic criteria. A total of 62 were male (21%); 117 (40%) were Hispanic, 90 (31%) Caucasian, and 59 (20%) African American. Mean age (±standard deviation) at diagnosis was 12•3 ± 3•8 (range 3-18•5) years. At diagnosis, 268 patients were started on an antithyroid drug and 23 underwent thyroid ablation or thyroidectomy. Fifty-seven (21%) children achieved remission and 16 (28%) of these patients relapsed, almost all within 16 months. Gender and ethnicity did not affect rates of remission or relapse. Of 251 patients treated with methimazole, 53 (21%) had an adverse reaction, including rash, arthralgias, elevated transaminases, or neutropenia.
Conclusions:
Most children with Graves’ disease treated with ATD do not experience remission, but most remissions do not end in relapse. Adverse reactions to methimazole are common but generally mild.
DOI: 10.1111/cen.13099
read more
myBinderRelated Content
-
Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapiesPurpose : Teprotumumab was approved as...
-
Graves’ DiseaseGraves disease is the most common cause ...
-
Management of Graves’ Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
-
Impact of Potassium Iodide on Thyroidectomy for Graves’ Disease: Implications for Safety and Operative Difficu...Background: Potassium iodide (KI) is of...
-
Glucocorticoid Regimens for Prevention of Graves’ Ophthalmopathy Progression Following Radioiodine Treatment: ...Background: Glucocorticoid (GC) therapy...
-
Debate Over Universal Screening for Thyroid Dysfunction in Pregnancy Centers on What to TreatThe question about screening for thyroid...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google